

Rec Ref	IRAS No	Full Title	Date Site Invited	Date Site Selected (DSS)	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed (DSC)	Date Site Ready To Start	Date First Participant Recruited (DFPR)	DSS to DSC (Days)	DSC to DFPR (Days)	DSS to DFPR (Days)	Comments	Reasons for delay:
16/SC/0462	208830	DRAFFT2: Distal Radius Acute Fracture Fixation Trial 2. A multi-centre, two arm, randomised controlled trial.	12/05/2017	05/10/2017	11/11/2016	06/10/2017	16/10/2017	19/10/2017	23/11/2017	11	38	49	2 Week window to recruit DRAFFT 2 patients, by the time patients are seen in fracture clinic they have already passed the 2 week window.	Neither
17/LO/1476	224732	A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0	29/06/2017	05/12/2017	19/10/2017	05/12/2017	06/12/2017	11/12/2017	26/01/2018	1	51	52	Complex eligibility criteria. No suitable patients seen in clinic within 30 days of study opening	Neither

Performance of Initiation. Year 2018-19, Q2 July-September

17/YH/0262	219133	TRITON Trial: Treatment of Irritable bowel syndrome using Titrated Ondansetron. This study is a phase III, parallel group randomised, double-blind, multi-centre, placebo-controlled, with embedded mechanistic studies within selected centres.	09/10/2017	13/02/2018	07/11/2017	14/02/2018	20/03/2018	18/04/2018		35			1 patient screened, but screen failure	Neither
16/WS/0132	199215	COLCOT - Colchicine Cardiovascular Outcomes Trial.	10/10/2017	02/02/2018	22/11/2016	06/03/2018	12/03/2018	16/03/2018	21/03/2018	38	9	47		Neither
17/LO/0962	220190	PREP - Pregnancy Trial of E-cigarettes and Patches.	31/07/2017	03/01/2018	24/07/2017	09/01/2018	24/01/2018	24/01/2018	12/02/2018	21	19	40		Neither
15/WM/0268	180518	Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma	08/11/2017	12/02/2018	26/08/2016	29/01/2018	16/02/2018	06/03/2018	08/05/2018	4	81	85	Strict inclusion criteria, no patient eligible	NHS Provider

Performance of Initiation. Year 2018-19, Q2 July-September

14/NE/1180	145170	Effectiveness of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome.	09/01/2018	15/02/2018	06/01/2017	01/03/2018	21/03/2018	21/03/2018	23/03/2018	34	2	36		Neither
16/SS/0128	203772	A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients upon discharge or following hospitalization for worsening chronic heart failure with left ventricular systolic dysfunction	28/06/2017	27/02/2018	10/11/2017	05/02/2018	14/05/2018	23/05/2018		76			Premature termination of the trial (administrative issues)	Sponsor

Performance of Initiation. Year 2018-19, Q2 July-September

16/NS/0053	201313	A randomised controlled trial comparing laparoscopic cholecystectomy with observation/conservative management for preventing recurrent symptoms and complications in adults with uncomplicated symptomatic gallstones	16/03/2018	16/05/2018	01/09/2016	12/06/2018	10/07/2018	10/07/2018	14/08/2018	55	35	90	No patient eligible	Both
17/NW/0529	226070	The impact of postoperative Packing of Perianal Abscess Cavities: a multicentre randomised controlled trial	09/05/2018	12/06/2018	05/12/2017	07/06/2018	17/07/2018	24/08/2018	13/09/2018	35	58	93	Awaiting greenlight from sponsor	Sponsor

Performance of Initiation. Year 2018-19, Q2 July-September

16/NE/0238	204031	The British Heart Foundation older patients with non-ST SEgmeNt elevatIO n myocaRdial infarction Randomized Interventional TreAtment Trial	01/05/2018	15/06/2018	08/08/2016	06/06/2018	09/07/2018	09/07/2018	16/07/2018	24	7	31		Neither
16/NE/0169	203949	A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND	18/01/2017	06/07/2018	27/06/2016	10/07/2018	30/07/2018	30/07/2018		24			Awaiting greenlight from sponsor	Sponsor

Performance of Initiation. Year 2018-19, Q2 July-September

16/WM/0036	180476	Accuracy of a rapid intrapartum test for maternal group B streptococcal colonisation and its potential to reduce antibiotic usage in mothers with risk factors	29/06/2017	07/07/2018	23/08/2016	07/02/2018	17/07/2018	17/07/2018	24/07/2018	10	7	17		Neither
17/LO/1060	187783	RANDOMISED DOUBLE-BLIND EFFICACY AND MECHANISM STUDY OF SUB-SENSORY SACRAL (OPTIMISED) NEUROMODULATION IN ADULTS WITH FAECAL INCONTINENCE	13/06/2017	10/07/2018	29/09/2017	11/06/2018	10/07/2018	10/07/2018		0			Strict inclusion criteria, no patient eligible	Neither

Performance of Initiation. Year 2018-19, Q2 July-September

17/LO/0334	214459	FLO-ELA: FLuid Optimisation in Emergency LAparotomy. Open, multi-centre, randomised controlled trial of cardiac output - guided haemodynamic therapy compared to usual care in patients undergoing emergency bowel surgery.	13/07/2017	17/07/2018	17/05/2018	17/04/2018	17/07/2018	05/09/2018		0			Awaiting greenlight from sponsor	Sponsor
17/EM/0077	206480	LACunar Intervention (LACI-2) Trial-2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease	05/06/2018	26/07/2018	24/07/2017	06/09/2018	19/09/2018	20/09/2018		55			Awaiting greenlight from sponsor	Sponsor

Performance of Initiation. Year 2018-19, Q2 July-September

16/WM/050 2	200319	Cognitive Behavioural Therapy to reduce anxiety and depression in patients with atrial fibrillation (CBT-AF)	05/12/2016	18/09/2018	26/02/2017	18/07/2016	25/09/2018	25/09/2018		7					Neither
----------------	--------	--	------------	------------	------------	------------	------------	------------	--	---	--	--	--	--	---------